Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 24, 2014 10:58am

182 Views

Post# 22486096

RE:RE:RE:RE:NISSEN INTERVIEW DURING. THIS MONTHS ACC

Great thinking Sanfran.

It would be excellent to here from biotech on the apoa 1 issue in terms of it's regained credibility as he had commented on it in previous posts.

My initial thought re Dr Nissan was that perhaps he had some sort of grudge with Don but you've cleared this up.
Cheers
Toinv

Bullboard Posts

Canadian rare earths stock up as drilling starts at uranium property